Literaturverzeichnis


(10) Crooke ST, Brandner WT: Mitomycin C, a review. Cancer Treat Rep 3 (1976) 121


(22) Godfrey TE, Wilbur DW: Clinical experience with mitomycin C in large infrequent dose. Cancer 29 (1972) 1647-1652


(41) Machover D, Diaz-Rubio, de Gramont A: Two consecutive phase II study of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidine. Ann Oncol 7(1996)


(45) Moertel CG, Reitmeier R, Hahn R: Mitomycin C therapy in advanced gastrointestinal cancer. JAMA 204 (1968) 1045-1048


(48) Nordic Gastrointestinal Tumor Adjuvant Therapy Expectancy or Primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J clin Oncol 10 (1992) 904-911


(55) Rothenberg ML, Oza AM, Bigelow RH: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin. Interim results of a


(59) Sartorelli AC, Booth BA: The synergistic anti-neoplastic activity of combinations of mitomycin C with either 6-thioguanine or 5-fluorouracil. Cancer Res 25 (1965) 1393-1400


(68) Tomasz M, Chowdary D, Lipman R: Reaction of DNA with chemically or enzymatically activated mitomycin C “Isolation and Structure of the major covalent adduct”. Proc Natl Acad Sci 83 (1986) 6702


(70) Twelwes C, Boyer M, Findly M: Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in


(77) Weh H, Zschaber R, Braumann D: A randomised phase III study comparing weekly folic acid (FA) and high-dose 5-fluorouracil (5FU) with monthly 5FU/FA (days 1-5) in untreated patients with metastatic colorectal carcinoma. Oncol 21(1998) 403-407